Literature DB >> 10694652

Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma.

S Kakar, M Mihalov, N A Chachlani, L Ghosh, H Johnstone.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694652     DOI: 10.1002/(sici)1096-9098(200002)73:2<125::aid-jso14>3.0.co;2-5

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


× No keyword cloud information.
  5 in total

1.  Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma.

Authors:  Rex C Haydon; Andrea Deyrup; Akira Ishikawa; Robert Heck; Wei Jiang; Lan Zhou; Tao Feng; David King; Hongwei Cheng; Benjamin Breyer; Terrance Peabody; Michael A Simon; Anthony G Montag; Tong-Chuan He
Journal:  Int J Cancer       Date:  2002-12-01       Impact factor: 7.396

Review 2.  Prognostic value of p53 alterations in human osteosarcoma: a meta analysis.

Authors:  Dong Yao; Guo-Hong Cai; Jing Chen; Rui Ling; Sheng-Xi Wu; Yong-Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  Gene expression profiling of taxol-resistant nasopharyngeal carcinoma cells with siRNA-mediated FOLR1 downregulation.

Authors:  Yexun Song; Xiaowei Peng; Min Wang; Jun Xie; Guolin Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Global protein-expression analysis of bone and soft tissue sarcomas.

Authors:  Akira Kawai; Tadashi Kondo; Yoshiyuki Suehara; Kazutaka Kikuta; Setsuo Hirohashi
Journal:  Clin Orthop Relat Res       Date:  2008-06-06       Impact factor: 4.176

5.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.